ADx NeuroSciences and Alamar Biosciences Announce Partnership to Provide Customized Blood-Based Biomarker Assay Solutions to Accelerate Biopharma Clinical Development

Contributed by: Business Wire

Logo

Images

Alamar Biosciences logo (Graphic: Business Wire)

ADx NeuroSciences logo (Graphic: Business Wire)

Business Wire embedded0

Tags

Research

Neurology

Clinical Trials

Biotechnology

Health

Pharmaceutical

General Health

Other Science

Science

Partnership

More Like This

PR Newswire associated0

Alamar Biosciences Announces the Commercial Launch of Ultra-high Sensitivity NULISAseq™ CNS Disease Panel 120 and NULISAqpcr™ pTau-217 Assays

GlobeNewswire associated0

Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

Biognosys Announces Commercial Availability of NULISA™ Proteomics Assay Services for Biomarker Research

PR Newswire associated0

Alamar Biosciences Announces Commercial Launch of the ARGO™ HT System and the NULISAseq™ Inflammation Panel 250 for Ultra-high Sensitivity Protein Analysis in Biofluids

PR Newswire associated0

Alamar Biosciences Announces Collaboration with The Michael J. Fox Foundation to Advance Parkinson's Research Through Development of Next Generation Biomarker Assays

Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

PR Newswire associated0

Alamar Biosciences and ALZpath, Inc. Announce Strategic Supply Agreement for pTau217 Antibody to Advance Alzheimer's Disease Research